Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Robins

Showing results (21-30 of 587) with videos related to

Pageof 59
Sort By:
Natural Product Reports|December 1, 1989
Pyrrolizidine alkaloidsD J Robins
Natural Product Reports|August 1, 1986
Pyrrolizidine alkaloidsD J Robins
Nucleosides & Nucleotides|August 5, 1999
Mechanism-based inhibition of ribonucleotide reductases: new mechanistic considerations and promising biological applicationsM J Robins
Natural Product Reports|June 1, 1984
Pyrrolizidine alkaloidsD J Robins
Current Cardiology Reports|November 1, 2005
Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndromeSander J Robins
Hospital & Community Psychiatry|April 1, 1974
Management-by-objectives for community mental health programsA J Robins
Natural Product Reports|October 1, 1987
Pyrrolizidine alkaloidsD J Robins
Natural Product Reports|June 1, 1985
Pyrrolizidine alkaloidsD J Robins
Administration in Mental Health|January 1, 1976
Governing boards and decision makingA J Robins
Journal of Cardiovascular Risk|September 12, 2001
PPARalpha ligands and clinical trials: cardiovascular risk reduction with fibratesS J Robins
Pageof 59

Showing results (21-30 of 587) with videos related to

Sort By:
Pageof 59
Natural Product Reports|December 1, 1989
Pyrrolizidine alkaloidsD J Robins
Natural Product Reports|August 1, 1986
Pyrrolizidine alkaloidsD J Robins
Nucleosides & Nucleotides|August 5, 1999
Mechanism-based inhibition of ribonucleotide reductases: new mechanistic considerations and promising biological applicationsM J Robins
Natural Product Reports|June 1, 1984
Pyrrolizidine alkaloidsD J Robins
Current Cardiology Reports|November 1, 2005
Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndromeSander J Robins
Hospital & Community Psychiatry|April 1, 1974
Management-by-objectives for community mental health programsA J Robins
Natural Product Reports|October 1, 1987
Pyrrolizidine alkaloidsD J Robins
Natural Product Reports|June 1, 1985
Pyrrolizidine alkaloidsD J Robins
Administration in Mental Health|January 1, 1976
Governing boards and decision makingA J Robins
Journal of Cardiovascular Risk|September 12, 2001
PPARalpha ligands and clinical trials: cardiovascular risk reduction with fibratesS J Robins
Pageof 59